Foundation Medicine's Revenues Climb 54 Percent in Q3 as Net Loss Widens | GenomeWeb

NEW YORK (GenomeWeb) – Foundation Medicine after the close of market Tuesday reported a 54 percent increase in revenues for the third quarter, driven by strong growth from its biopharmaceutical business, along with a widening net loss and a sequential decrease in the number of clinical tests it provided.

Investors reacted negatively to the shortfall in clinical tests and a lowered forecast for 2015 clinical test volume, sending Foundation Medicine’s shares down 21 percent in Wednesday morning trade on the Nasdaq to $18.91.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.